King of Prussia-based XyloCor Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, recently appointed John Tucker as president and CEO, effective immediately.
Tucker will also join the board of directors, effective immediately.
“John is a proven leader with deep expertise in cardiovascular medicine and a strong track record of building innovative biotechnology organizations,” Pascal Touchon, XyloCor Therapeutics board member, said. “His strategic vision, operational discipline and commitment to patients make him exceptionally well suited to lead XyloCor. Under his leadership, the company is well positioned to further accelerate the development of transformative therapies for patients with cardiovascular disease.”
Tucker has more than 20 years of leadership experience in the biotechnology and life sciences industries that includes IPO execution, advancing clinical programs, leading fundraising initiatives, regulatory approvals and commercialization efforts, building high-performing teams, and driving strategic growth.
He comes to the company from scPharmaceuticals where he served as CEO. He previously was Alcresta Therapeutics CEO.
“John is a dynamic and visionary leader with the operational expertise and strategic insight needed to guide XyloCor through its next phase of development,” Glenn Batchelder, board chairman, said.
XC001, XyloCor’s lead product candidate, is in clinical development for use in patients with coronary artery disease and refractory angina.